The development of insulin confrontation that leads to type 2 diabetes could be due to an immune system reaction. New research has recognized immune system antibodies among obese people who are insulin-resistant that are not found in people absent insulin resistance. The findings of the study were newly published online in the journal Nature Medicine. According to learn co-author Dr. Daniel Winer, an endocrine pathologist at the University Health Network of the University of Toronto in Ontario, Canada, “We are in the progression of redefining one of the most ordinary diseases in American as an autoimmune disease, rather than a purely metabolic disease.”
He went on to explain, “This work will alter the way people think about obesity, and will likely impact medicine for years to come as physicians begin to switch their focus to immune alter treatments for type 2 diabetes.” Winer, along with his twin brother, Shawn Winer, of the Hospital for Sick Children at the University of Toronto, and Stanford research relate Lei Shen are co-first authors of the study. Winer was a postdoctoral fellow at Stanford University in California while the research began.
Almost 26 million Americans suffer from diabetes, according to the U.S. Centers for Disease Control and Prevention. The vast mass of cases are type 2 diabetes. With type 2 diabetes, the body either does not manufacture enough insulin, or the boy’s cells ignore the insulin. The body needs insulin in order to use glucose for energy. When food is consumed, sugars and starches are broken down into glucose to fuel the body’s cells, and insulin move it from the blood into the cells. A build up of glucose in the blood that is not full to the cells leads to diabetes complications. In Type 1 diabetes, defined as an autoimmune disease, the body fails to create insulin due to destruction of the insulin-producing beta cells in the pancreas by the immune system.
He went on to explain, “This work will alter the way people think about obesity, and will likely impact medicine for years to come as physicians begin to switch their focus to immune alter treatments for type 2 diabetes.” Winer, along with his twin brother, Shawn Winer, of the Hospital for Sick Children at the University of Toronto, and Stanford research relate Lei Shen are co-first authors of the study. Winer was a postdoctoral fellow at Stanford University in California while the research began.
Almost 26 million Americans suffer from diabetes, according to the U.S. Centers for Disease Control and Prevention. The vast mass of cases are type 2 diabetes. With type 2 diabetes, the body either does not manufacture enough insulin, or the boy’s cells ignore the insulin. The body needs insulin in order to use glucose for energy. When food is consumed, sugars and starches are broken down into glucose to fuel the body’s cells, and insulin move it from the blood into the cells. A build up of glucose in the blood that is not full to the cells leads to diabetes complications. In Type 1 diabetes, defined as an autoimmune disease, the body fails to create insulin due to destruction of the insulin-producing beta cells in the pancreas by the immune system.
No comments:
Post a Comment